VSC 4 SC AG

4SC AG (Frankfurt, Prime Standard: VSC) a drug discovery and development company, will announce its financial results 2009 (ended 31 December, 2009) on 30 March, 2010. The senior management team will host a conference call at 3pm CET (10am EST) on the day to inform about the financial results and all important developments in the reporting period.

Access to the presentation slides can be obtained at: http://www.cyber-presentation.de/cgi-bin/visitors.ssp?fn=visitor&id=1163

Date: 30 March, 2010

Time: 3pm CET (10am EST)

Dial-in numbers:

0800 10 12 072 (Germany)

0800 358 0886 (UK)

+1 877 941 6012 (USA)

+49 (0) 6958 999 0805 (other countries)

Conference ID: 4265406

Approximately two hours after the live presentation, an audio replay of the conference will be available on the 'investors' section of the homepage www.4sc.com.

For further information please contact: Yvonne Alexander   Investor & Public Relations 4SC AG Tel.: +49 (0) 89 70 07 63 - 66

yvonne.alexander@4sc.com

About 4SC

4SC AG (ISIN DE0005753818) is a drug discovery and development company focused on autoimmune and cancer indications. Vidofludimus (4SC-101), a small molecule, is currently in a Phase IIb study in rheumatoid arthritis and a Phase IIa exploratory study in inflammatory bowel disease. The company's lead oncology compound, resminostat (4SC-201), a pan histone deacetylase (HDAC) inhibitor, is in Phase II trials in hepatocellular carcinoma and Hodgkin's lymphoma. Two further oncology compounds, 4SC-203 and 4SC-205, are in Phase I studies. 4SC develops drug candidates until proof-of-concept in order to generate value creating partnerships with the pharmaceutical industry in return for advance and milestone payments as well as royalties.

4SC was founded in 1997, has 93 employees, and is listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

For further information please visit www.4sc.com.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

Language:   English Company: 4SC AG Am Klopferspitz 19a 82152 Martinsried Deutschland Phone: +49 (0)89 7007 63-0 Fax: +49 (0)89 7007 63-29 E-mail:

public@4sc.com

Internet:

www.4sc.de

ISIN: DE0005753818 WKN: 575381 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart